Therapeutic Solutions International, Inc. (TSOI)
| Previous close | 0.0006 |
| Open | 0.0006 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0005 - 0.0008 |
| 52-week range | 0.0004 - 0.0033 |
| Volume | |
| Avg. volume | 23,334,226 |
| Market cap | 3.384M |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients
ELK CITY, Idaho, March 04, 2024--Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the ability of QuadraMune® and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19. NK cells are the first line of defense against viruses and cancers1.
- Business Wire
Therapeutic Solutions International Announces Landmark Finding Regarding Mechanism of Action of its JadiCell Stem Cell Product
ELK CITY, Idaho, February 29, 2024--Therapeutic Solutions International, Inc. (TSOI), announced today results of ongoing experiments demonstrating that the healing effects of JadiCells appear to be mediated by a biological mechanism involving interplay between two types of immunological cells found in the body.
- Business Wire
Therapeutic Solutions International Files Patent on "Facilitating Effects" of JadiCells on Gene Therapy Mediated Cell Differentiation
ELK CITY, Idaho, February 26, 2024--Therapeutic Solutions International, Inc. (TSOI), announced today data demonstrating that JadiCell administration is capable of increasing gene therapy mediated production of therapeutic cells in vivo.
